Insider Trading Activity Novavax, Inc. (NASDAQ:NVAX) – CFO Bought 2,057 shares of Stock

ME Staff
-
0

Insider Trading Activity For Novavax, Inc. (NASDAQ:NVAX)

Barclay A. Phillips , CFO of Novavax, Inc. (NASDAQ:NVAX) reportedly Bought 2,057 shares of the company’s stock at an average price of 0.89 for a total transaction amount of $1,830.73 SEC Form

Insider Trading History For Novavax, Inc. (NASDAQ:NVAX)

  • On 3/11/2013 James F Young, Director, bought 100,000 with an average share price of $2.03 per share and the total transaction amounting to $203,000.00.View SEC Filing
  • On 6/6/2013 James F Young, Director, bought 100,000 with an average share price of $1.91 per share and the total transaction amounting to $191,000.00.View SEC Filing
  • On 6/7/2013 Gregory M Glenn, Insider, bought 2,000 with an average share price of $1.92 per share and the total transaction amounting to $3,840.00.View SEC Filing
  • On 6/10/2013 Timothy Jon Hahn, SVP, bought 21,000 with an average share price of $1.88 per share and the total transaction amounting to $39,480.00.View SEC Filing
  • On 6/12/2013 Richard Douglas, Director, bought 50,000 with an average share price of $1.90 per share and the total transaction amounting to $95,000.00.View SEC Filing
  • On 1/31/2014 Timothy Jon Hahn, SVP, bought 9,416 with an average share price of $2.29 per share and the total transaction amounting to $21,562.64.View SEC Filing
  • On 1/31/2014 Stanley Erck, CEO, bought 11,868 with an average share price of $2.29 per share and the total transaction amounting to $27,177.72.View SEC Filing

    • Analyst Ratings For Novavax, Inc. (NASDAQ:NVAX)
    These are 7 Hold Ratings, 2 Buy Ratings .
    The current consensus rating for Novavax, Inc. (NASDAQ:NVAX) is Hold (Score: 2.22) with a consensus target price of $5.77 , a potential (460.32% upside)

    Analyst Ratings History For Novavax, Inc. (NASDAQ:NVAX)

    • On 8/29/2016 Guggenheim Reiterated Rating Buy with a price target of $25.00
    • On 9/16/2016 Citigroup Inc. Downgraded rating Buy to Neutral with a price target of $12.00 to $1.50 with a price target of $1.44 to $1.17
    • On 11/10/2016 J P Morgan Chase & Co Reiterated Rating Hold
    • On 11/11/2016 Wedbush Reiterated Rating Neutral with a price target of $2.00 to $1.50
    • On 1/18/2017 FBR & Co Reiterated Rating Outperform with a price target of $12.00
    • On 3/1/2017 Ladenburg Thalmann Financial Services Reiterated Rating Neutral

    Recent Trading Activity for Novavax, Inc. (NASDAQ:NVAX)
    Shares of Novavax, Inc. closed the previous trading session at 1.03 down -0.01 -0.96% with 3,960,410 shares trading hands.